Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.73 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.68 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308677 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL15384692 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18308678 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21937225 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14194625 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23783591 | 1.00 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21339332 | 0.98 | FOLH1 (0.71) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL16374659 | 0.95 | FOLH1 (0.70) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL30255156 | 0.94 | FOLH1 (0.66) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24729088 | 0.94 | FOLH1 (0.66) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20130202652-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012016188-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20130202652-A1 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS | FUCA1, FUCA2, ANXA2 | FOLH1 10/4885NAALAD2 1041/4885RIMKLA 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.